Acquired lymphedema: Molecular contributors and future directions for developing intervention strategies
Lymphedema is a debilitating chronic disease that mostly develops as an adverse reaction to cancer treatment modalities such as chemotherapy, surgery, and radiotherapy. Lymphedema also appears to be a deteriorating consequence of roundworm infections, as best represented by filariasis. According to...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-10-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.873650/full |
| _version_ | 1811234360158846976 |
|---|---|
| author | Ika Nurlaila Ika Nurlaila Kangsan Roh Kangsan Roh Chang-Hwan Yeom Hee Kang Sukchan Lee |
| author_facet | Ika Nurlaila Ika Nurlaila Kangsan Roh Kangsan Roh Chang-Hwan Yeom Hee Kang Sukchan Lee |
| author_sort | Ika Nurlaila |
| collection | DOAJ |
| description | Lymphedema is a debilitating chronic disease that mostly develops as an adverse reaction to cancer treatment modalities such as chemotherapy, surgery, and radiotherapy. Lymphedema also appears to be a deteriorating consequence of roundworm infections, as best represented by filariasis. According to its origin, lymphedema is classified as primary lymphedema and acquired lymphedema. The latter is an acquired condition that, hitherto, received a considerably low attention owing to the less number of fatal cases been reported. Notably, despite the low mortality rate in lymphedema, it has been widely reported to reduce the disease-free survival and thus the quality of life of affected patients. Hence, in this review, we focused on acquired lymphedema and orchestration of molecular interplays associated with either stimulation or inhibition of lymphedema development that were, in vast majority, clearly depicted in animal models with their specific and distinct technical approaches. We also discussed some recent progress made in phytochemical-based anti-lymphedema intervention strategies and the specific mechanisms underlying their anti-lymphedema properties. This review is crucial to understand not only the comprehensive aspects of the disease but also the future directions of the intervention strategies that can address the quality of life of affected patients rather than alleviating apparent symptoms only. |
| first_indexed | 2024-04-12T11:36:25Z |
| format | Article |
| id | doaj.art-78da01009c7140e08fb377b45bd6cb03 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-04-12T11:36:25Z |
| publishDate | 2022-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-78da01009c7140e08fb377b45bd6cb032022-12-22T03:34:50ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122022-10-011310.3389/fphar.2022.873650873650Acquired lymphedema: Molecular contributors and future directions for developing intervention strategiesIka Nurlaila0Ika Nurlaila1Kangsan Roh2Kangsan Roh3Chang-Hwan Yeom4Hee Kang5Sukchan Lee6Department of Integrative Biotechnology, Sungkyunkwan University, Suwon, South KoreaDepartment of Vaccine and Drugs, The National Research and Innovation Agency, Jakarta, IndonesiaCardiovascular Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United StatesDivision of Cardiology and Corrigan Minehan Heart Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United StatesYeom Chang-Hwan Hospital, Seoul, South KoreaHumanitas College, Kyung Hee University, Yongin, South KoreaDepartment of Integrative Biotechnology, Sungkyunkwan University, Suwon, South KoreaLymphedema is a debilitating chronic disease that mostly develops as an adverse reaction to cancer treatment modalities such as chemotherapy, surgery, and radiotherapy. Lymphedema also appears to be a deteriorating consequence of roundworm infections, as best represented by filariasis. According to its origin, lymphedema is classified as primary lymphedema and acquired lymphedema. The latter is an acquired condition that, hitherto, received a considerably low attention owing to the less number of fatal cases been reported. Notably, despite the low mortality rate in lymphedema, it has been widely reported to reduce the disease-free survival and thus the quality of life of affected patients. Hence, in this review, we focused on acquired lymphedema and orchestration of molecular interplays associated with either stimulation or inhibition of lymphedema development that were, in vast majority, clearly depicted in animal models with their specific and distinct technical approaches. We also discussed some recent progress made in phytochemical-based anti-lymphedema intervention strategies and the specific mechanisms underlying their anti-lymphedema properties. This review is crucial to understand not only the comprehensive aspects of the disease but also the future directions of the intervention strategies that can address the quality of life of affected patients rather than alleviating apparent symptoms only.https://www.frontiersin.org/articles/10.3389/fphar.2022.873650/fulllymphedematherapyphytochemicalsadipogenesisfibrosisanimal models |
| spellingShingle | Ika Nurlaila Ika Nurlaila Kangsan Roh Kangsan Roh Chang-Hwan Yeom Hee Kang Sukchan Lee Acquired lymphedema: Molecular contributors and future directions for developing intervention strategies Frontiers in Pharmacology lymphedema therapy phytochemicals adipogenesis fibrosis animal models |
| title | Acquired lymphedema: Molecular contributors and future directions for developing intervention strategies |
| title_full | Acquired lymphedema: Molecular contributors and future directions for developing intervention strategies |
| title_fullStr | Acquired lymphedema: Molecular contributors and future directions for developing intervention strategies |
| title_full_unstemmed | Acquired lymphedema: Molecular contributors and future directions for developing intervention strategies |
| title_short | Acquired lymphedema: Molecular contributors and future directions for developing intervention strategies |
| title_sort | acquired lymphedema molecular contributors and future directions for developing intervention strategies |
| topic | lymphedema therapy phytochemicals adipogenesis fibrosis animal models |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2022.873650/full |
| work_keys_str_mv | AT ikanurlaila acquiredlymphedemamolecularcontributorsandfuturedirectionsfordevelopinginterventionstrategies AT ikanurlaila acquiredlymphedemamolecularcontributorsandfuturedirectionsfordevelopinginterventionstrategies AT kangsanroh acquiredlymphedemamolecularcontributorsandfuturedirectionsfordevelopinginterventionstrategies AT kangsanroh acquiredlymphedemamolecularcontributorsandfuturedirectionsfordevelopinginterventionstrategies AT changhwanyeom acquiredlymphedemamolecularcontributorsandfuturedirectionsfordevelopinginterventionstrategies AT heekang acquiredlymphedemamolecularcontributorsandfuturedirectionsfordevelopinginterventionstrategies AT sukchanlee acquiredlymphedemamolecularcontributorsandfuturedirectionsfordevelopinginterventionstrategies |